While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious? Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest Emmy award-winning journalist John Donvan moderates Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.